Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy—the MecMeth/NOA-24 trial

BACKGROUND: Glioblastoma is the most frequent and malignant primary brain tumor. Even in the subgroup with O-6-methylguanine-DNA methyltransferase (MGMT) promoter methylation and favorable response to first-line therapy, survival after relapse is short (12 months). Standard therapy for recurrent MGM...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeyen, Thomas, Potthoff, Anna-Laura, Nemeth, Robert, Heiland, Dieter H., Burger, Michael C., Steinbach, Joachim P., Hau, Peter, Tabatabai, Ghazaleh, Glas, Martin, Schlegel, Uwe, Grauer, Oliver, Krex, Dietmar, Schnell, Oliver, Goldbrunner, Roland, Sabel, Michael, Thon, Niklas, Delev, Daniel, Clusmann, Hans, Seidel, Clemens, Güresir, Erdem, Schmid, Matthias, Schuss, Patrick, Giordano, Frank A., Radbruch, Alexander, Becker, Albert, Weller, Johannes, Schaub, Christina, Vatter, Hartmut, Schilling, Judith, Winkler, Frank, Herrlinger, Ulrich, Schneider, Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8767701/
https://www.ncbi.nlm.nih.gov/pubmed/35045869
http://dx.doi.org/10.1186/s13063-021-05977-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8767701/
https://www.ncbi.nlm.nih.gov/pubmed/35045869
http://dx.doi.org/10.1186/s13063-021-05977-0

Ejemplares similares